Results 141 to 150 of about 16,460 (261)

Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding

Frontiers in Immunology
BackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target.
Liang Huang, Chao Kong, Chao Kong, Yuhao Hu, Michael Zhang, Shuangqi Li, Wanjing Wang, Hui Guan, Mei Ling Lim, Zhen Zhang, Wenhai Zhang, Hailiang Zheng, Xintian Yan, Xinglu Sun, Pan Lei, Shanshan Dai, Wenrong Wang, Linlin Lu, Junma Zhou, Shilong Fan, Guojun Lang   +20 more
doaj   +1 more source

Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler

Developability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel biotherapeutics such as nanobodies is more limited. Differences
Souders, Colby, Gordon, Gemma L, Gervasio, João, Deane, Charlotte M   +3 more
core   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

The development of nanobody-functionalized gold surfaces

Die Rasterkraftmikroskopie ermöglicht eine dreidimensionale Darstellung von Proben. Dabei  ist es eine etablierte Methode, dass mithilfe von Antikörpern die Genauigkeit dieser Mikroskopie verbessert wird.
Munsch, Cornel
core   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Modulating ion channels with nanobodies

Synthetic and Systems Biotechnology
Ion channels play instrumental roles in regulating membrane potential and cross-membrane signal transduction, thus making them attractive targets for understanding various physiological processes and associated diseases. Gaining a deeper understanding of their structural and functional properties has significant implications for developing therapeutic ...
Sher Ali, Ashley Suris, Yun Huang, Yubin Zhou   +3 more
openaire   +3 more sources

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

CKLF‐like MARVEL transmembrane domain‐containing superfamily 8 (CMTM8) promotes Notch signalling to maintain CD8+ T cell‐ and NK cell‐dependent tumour immune escape

British Journal of Pharmacology, EarlyView.
Background and Purpose The CKLF‐like MARVEL transmembrane domain containing superfamily (CMTM) has an important role in tumour immunity. The role of CMTM8 in tumour immune microenvironment (TIME) remains unknown. The aim was to investigate the relationship between CMTM8 and antitumour immunity. Experimental Approach Lentiviral system was established to
Fanglin Li, Longhua Gu, Runqiu Chen, Zhiying Li, Rong Zhang, Chen Chen, Yi Liu, Xinhang Zheng, Yiting Wang, Shanna Wu, Jianhua Sun, Jing Chen, Bingshun Wang, Likun Gong, Yiru Long   +14 more
wiley   +1 more source